Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887510 · ClinicalTrials.gov registry record · Phase 4
Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00887510 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 24 participants.
The verdict
NCT00887510, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
High blood pressure, also referred to as hypertension, is a blood pressure level of 140/90 mm Hg or higher. Along with lifestyle changes, various medications are currently used to treat people with hypertension. Some of these medications, however, may affect the way the body handles sugar, essentially preventing the body from breaking down sugar and predisposing people to developing diabetes. People who have metabolic syndrome-a condition primarily characterized by an increased waist measurement, abnormal blood lipid levels, hypertension, and high blood sugar levels-are already at risk of developing diabetes. In these people, taking the antihypertensive medications that prevent sugar breakdown may further increase their risk of diabetes. The purpose of this study is to gain an understanding of how people with metabolic syndrome respond to antihypertensive medications that alter the body's ability to break down sugar.
Interventions
- DRUG Hydrochlorothiazide
- DRUG Trandolapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887510
The ClinicalTrials.gov registry entry for NCT00887510 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide is the first listed.
NCT00887510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887510 about?
NCT00887510 is a clinical study titled "Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)". High blood pressure, also referred to as hypertension, is a blood pressure level of 140/90 mm Hg or higher. Along with lifestyle changes, various medications are currently used to treat people with hypertension. Some of these medications, however, may affect the way the body handles sugar, essential...
What is the current status of trial NCT00887510?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2007-05. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00887510?
The interventions under investigation include: Hydrochlorothiazide (DRUG), Trandolapril (DRUG).
Who is sponsoring clinical trial NCT00887510?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.